JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million

Stock News11-17

JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.

The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182754508?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182754508","market":"fut","top_or_hot":-1,"title":"JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million","media":"Stock News","content":"<p>JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.</p>\n<p>The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-17 18:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.</p>\n<p>The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1182754508","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182754508","pubTimestamp":1763376026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02161":"健倍苗苗","BK1606":"中医药概念"},"translate_title":"健邦医疗(02161)公布中期业绩：权益持有人应佔溢利按年升20.0%至约1.15亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02161":1},"content_text":"JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.\nThe company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182754508","isCrawlerRequest":true}